Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

LUN04-79

A Phase I-IIa Dose-Ranging Study of Pemetrexed (Alimta) Plus Cetuximab (Erbitux) in Patients With Recurrent Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN04-79

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

  • P. Bedano, M. Edelman, S. Nattam, D. Waterhouse, J. Shen, M. Yu, J. Harvey, J. Vinson, A. White, B. Bottema, N. Hanna. A Phase I-IIa Dose Ranging Study of Pemetrexed plus Cetuximab in Patients (pts) with Recurrent Non-Small Cell Lung Cancer (NSCLC): Analysis of the Completed Phase I Portion of HOG-LUN04-79. Poster presentation at the 4th IASLC International Chicago Symposium on Malignancies of the Chest and Head and Neck, October 26-28, 2006.

Manuscripts/Articles:

  • S. Jalal, D.Waterhouse, M. J. Edelman, S. Nattam, R. Ansari, K. Koneru, R. Clark, A.Richards, J. Wu, M. Yu, B. Bottema, A.White, N. Hanna. Pemetrexed plus Cetuximab in patients with Recurrent Non-Small Cell Lung Cancer (NSCLC): A Phase I/II Study from the Hoosier Oncology Group LUN04-79. Journal of Thoracic Oncology • Volume 4, Number 10, October 2009.